vimarsana.com

Latest Breaking News On - Ifinatamab deruxtecan - Page 1 : vimarsana.com

Merck: Keytruda Patent Expiry Nears With Replacement Yet To Be Found (NYSE:MRK)

Merck: Keytruda Patent Expiry Nears With Replacement Yet To Be Found (NYSE:MRK)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Investigators Deliver Updates on Evolving Clinical Trials Evaluating ADCs in Lung Cancer

Merck agrees to pay Daiichi up to $22B in record ADC agreement

Deals involving antibody-drug conjugate (ADC) therapies continue to gain momentum with Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. the latest firms to team up on global development and commercialization activities, as Daiichi offers up rights to three of its potentially first-in-class ADC candidates for $22 billion, making it the largest ADC agreement to date.

Ifinatamab Deruxtecan Demonstrates Robust Efficacy, Acceptable Safety in SCLC

Melissa L. Johnson, MD, spotlights the early-phase investigation of ifinatamab deruxtecan in advanced solid tumors, discusses the efficacy and safety of the agent in patients with small cell lung cancer, and emphasizes how results from a subgroup analysis support its continued investigation.

Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial

Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.